IMM 529
Alternative Names: IMM-529Latest Information Update: 11 Nov 2025
At a glance
- Originator Immuron
- Class Anti-infectives; Polyclonal antibodies
- Mechanism of Action Clostridium difficile toxB protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Clostridium difficile infections
Most Recent Events
- 05 Nov 2025 US FDA approves IND application for IMM 529 in Clostridium difficile infections (Adjunctive treatment, Combination therapy, Prevention)
- 05 Nov 2025 Immuron and Monash University plan a phase II trial for Clostridium difficile infections (Adjunctive treatment, Combination therapy, Prevention) in Australia (PO), in the first half of 2026
- 08 Oct 2025 Immuron files an IND application to the US FDA for IMM 529 in USA for Clostridium difficile infections